BRN2 is a non-canonical melanoma tumor-suppressor - Archive ouverte HAL Access content directly
Journal Articles Nature Communications Year : 2021

BRN2 is a non-canonical melanoma tumor-suppressor

Pierre Sohier
Véronique Delmas
Luis Sanchez-Del-Campo
Dies Meijer
Colin R Goding
  • Function : Author
  • PersonId : 1139078
Lionel Larue
  • Function : Author
  • PersonId : 922897

Abstract

While the major drivers of melanoma initiation, including activation of NRAS/BRAF and loss of PTEN or CDKN2A, have been identified, the role of key transcription factors that impose altered transcriptional states in response to deregulated signaling is not well understood. The POU domain transcription factor BRN2 is a key regulator of melanoma invasion, yet its role in melanoma initiation remains unknown. Here, in a Braf V600E Pten F/+ context, we show that BRN2 haplo-insufficiency promotes melanoma initiation and metastasis. However, metastatic colonization is less efficient in the absence of Brn2. Mechanistically, BRN2 directly induces PTEN expression and in consequence represses PI3K signaling. Moreover, MITF, a BRN2 target, represses PTEN transcription. Collectively, our results suggest that on a PTEN heterozygous background somatic deletion of one BRN2 allele and temporal regulation of the other allele elicits melanoma initiation and progression.
Fichier principal
Vignette du fichier
Hamm et al., 2021.pdf (5.59 Mo) Télécharger le fichier
Origin Files produced by the author(s)

Dates and versions

hal-03437816 , version 1 (20-11-2021)
hal-03437816 , version 2 (26-11-2021)

Licence

Identifiers

Cite

Michael Hamm, Pierre Sohier, Valérie Petit, Jérémy H Raymond, Véronique Delmas, et al.. BRN2 is a non-canonical melanoma tumor-suppressor. Nature Communications, 2021, 12 (1), pp.3707. ⟨10.1038/s41467-021-23973-5⟩. ⟨hal-03437816v2⟩
75 View
47 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More